Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417612 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
A Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00417612: Completed Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial, sponsored by Yale University.
NCT00417612 is a Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial that has completed, run by Yale University. The registered enrollment target is 33 participants, below the 129-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00417612, a Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of paricalcitol, a form of synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.
Primary Outcome
Mean area under the curve for parathyroid hormone levels (PTHauc) sampled during a 26 hour study period, for Paricalcitol (Active Drug) and Placebo groups at Baseline and Month 12 .
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Paricalcitol
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT00417612 record still lists
NCT00417612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 129-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00417612 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00417612 about?
NCT00417612 is a clinical study titled "Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets". The purpose of this study is to determine the effectiveness of paricalcitol, a form of synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.
What is the current status of trial NCT00417612?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2007-01. Estimated completion is 2012-08.
What conditions does trial NCT00417612 study?
This clinical trial studies the following conditions: Hyperparathyroidism, Hypophosphatemia, Familial.
What interventions are being tested in trial NCT00417612?
The interventions under investigation include: Placebo (OTHER), Paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00417612?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00417612 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
COMPLETED · Phase 3
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroidectomy and Mobility Study
RECRUITING
-
STP.168 Clinical Study Protocol Parakeet
ACTIVE NOT RECRUITING · NA
-
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
ACTIVE NOT RECRUITING · NA
-
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia